NCT06177522

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

A Single-arm, Single-center, Exploratory Study of Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Jinling Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Clinical Study on the Safety and Efficacy of the efficacy and safety of Adebrelimab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer

Detailed description

The goal of this clinical trial is to observe and evaluate the efficacy and safety of Adebrelimab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer.The main questions it aims to answer are: To investigate the feasibility of immunotherapy combined with chemotherapy in the neoadjuvant therapy of pancreatic cancer. To explore more effective neoadjuvant therapies for pancreatic cancer. Participants will receive 2 cycles of Adebrelimab in combination with albumin-bound paclitaxel and gemcitabine in the neoadjuvant phase, followed by surgery.

Conditions

• Pancreatic Cancer
• Neoadjuvant Therapy

Interventions

Type	Name	Description
DRUG	Adebrelimab	1200mg，i.v. , q3w
DRUG	albumin-bound paclitaxel	125 mg/m2, i.v.,d1,d8, q3w
DRUG	Gemcitabine	1.0 g/m2, i.v.,d1, d8, q3w

Timeline

• Start date: 2025-11-30
• Primary completion: 2027-12-30
• Completion: 2028-12-31
• First posted: 2023-12-20
• Last updated: 2025-11-18

Locations

1 site across 1 country: China